Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CLIC-1901 |
Synonyms | |
Therapy Description |
CLIC-1901 consists of non-cryopreserved autologous T-cells expressing a CD19-targeting chimeric antigen receptor (CAR), which potentially decreases tumor growth (PMID: 36601119). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CLIC-1901 | CLIC 1901|CLIC1901 | CD19 Immune Cell Therapy 62 | CLIC-1901 consists of non-cryopreserved autologous T-cells expressing a CD19-targeting chimeric antigen receptor (CAR), which potentially decreases tumor growth (PMID: 36601119). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |